Y-mAbs Therapeutics, Inc.

YMAB

US9842411095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.71 ^USD	-0.88%		-2.78%	+115.69%

Mar. 14	Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	MT
Mar. 14	Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	CI

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

February 29, 2024 at 04:05 pm EST

Y-mAbs Therapeutics, Inc. provided earnings guidance for the year 2024. The company anticipated DANYELZA net product revenues of between $95 million and $100 million.

Latest news about Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	Mar. 14	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	Mar. 14	CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	Mar. 14	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	Mar. 06	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	Mar. 04	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	Mar. 04	MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	Mar. 04	CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	Mar. 04	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	Mar. 01
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	Mar. 01	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	Feb. 29	MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	Feb. 20	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	Feb. 12	MT
Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	Jan. 10
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	Dec. 22	MT
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index	Dec. 18	CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18	Dec. 13	MT
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing	Nov. 29	MT
Y-mabs Therapeutics Insider Sold Shares Worth $795,383, According to a Recent SEC Filing	Nov. 22	MT
Transcript : Y-mAbs Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Y-mAbs Therapeutics Q3 Net Loss Narrows, Revenue Rises	Nov. 13	MT
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q3 Revenue $20.5M, vs. Street Est of $20.9M	Nov. 13	MT

Chart Y-mAbs Therapeutics, Inc.

Duration

Period

More charts

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Y-mAbs Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.71 USD

Average target price

21.67 USD

Spread / Average Target

+47.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Y-MABS THERAPEUTICS, INC.	+115.69%	644M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs